Skip to main content
Clinical Trials/NCT05301868
NCT05301868
Unknown
Not Applicable

A Multicenter Clinical Study to Evaluate the Efficacy and Feasibility of a 24-week Multidomain Intervention Via a None-face-to-face Platform in Mild Cognitive Impairment

Inha University Hospital4 sites in 1 country100 target enrollmentApril 11, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Mild Cognitive Impairment
Sponsor
Inha University Hospital
Enrollment
100
Locations
4
Primary Endpoint
Change of cognition
Last Updated
4 years ago

Overview

Brief Summary

This study will be done to investigate the feasibility and effectiveness of a 24-week multidomain intervention program consisting of cognitive training, exercise, nutrition management, vascular disease risk factor management, and motivational enhancement on the cognitive function via none-face-to-face platform in mild cognitive impairment.

Detailed Description

The physical exercise program will consist of aerobic exercise, exercise to enhance balance and flexibility, muscle-strengthening activities involving major muscle groups, and finger-toe movements. Cognitive training targets the cognitive domains of episodic memory, executive function, attention, working memory, calculation, and visuospatial function. Cognitive training will be conducted using a tablet-based application. Participants will be advised to eat something according to the recommendation of the Mediterranean-DASH Intervention for Neurodegenerative Delay diet (MIND) diet. They will be educated about vascular risk factor management every 2 weeks. The purpose of the motivational enhancement program is to induce, maintain, and strengthen motivation, which is a psychological resource to help maintain dementia prevention activities. All intervention will be administered via tablet personal computer (PC) application at home.

Registry
clinicaltrials.gov
Start Date
April 11, 2022
End Date
December 31, 2023
Last Updated
4 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Seong Hye Choi, MD

Professor

Inha University Hospital

Eligibility Criteria

Inclusion Criteria

  • Subjects who completed end-of-study evaluation and participated in the preceding randomized controlled trial (RCT) "Multidomain Interventions Via Face-to-face and Video Communication Platforms in Mild Cognitive Impairment".
  • Being able to use the tablet PC through education, or having a person who can help a participant use the tablet PC.
  • Having a reliable informant who could provide investigators with the requested information
  • Provide written informed consent

Exclusion Criteria

  • Major psychiatric illness such as major depressive disorders
  • Other neurodegenerative disease (e.g., Parkinson's disease)
  • Malignancy within 5 years
  • Cardiac stent or revascularization within 1 year
  • Serious or unstable symptomatic cardiovascular disease
  • Other serious or unstable medical disease such as acute or severe asthma, active gastric ulcer, severe liver disease, or severe renal disease
  • Severe loss of vision, hearing, or communicative disability
  • Any conditions preventing cooperation as judged by the study physician
  • Significant laboratory abnormality that may result in cognitive impairment
  • Illiteracy

Outcomes

Primary Outcomes

Change of cognition

Time Frame: Change from Baseline at 24 weeks

Repeatable Battery for the Assessment of Neuropsychological Status

Secondary Outcomes

  • Change of global cognition(Change from Baseline at 24 weeks)
  • Change of function(Change from Baseline at 24 weeks)
  • Change of subjective memory(Change from Baseline at 24 weeks)
  • Change of depression(Change from Baseline at 24 weeks)
  • Quality of life assessed by the Quality of life-Alzheimer's disease(Change from Baseline at 24 weeks)
  • Change of activities of daily living(Change from Baseline at 24 weeks)
  • Change of nutritional behavior(Change from Baseline at 24 weeks)
  • Change of nutrition(Change from Baseline at 24 weeks)
  • Change of motor function(Change from Baseline at 24 weeks)
  • Sleep quality assessed by the Pittsburgh Sleep Quality Index(Change from Baseline at 24 weeks)
  • Change of motivation(Change from Baseline at 24 weeks. Higher scores indicate better performance.)

Study Sites (4)

Loading locations...

Similar Trials